Latent Tuberculosis Infection Detection Market Size & Growth Forecast 2026–2035, By Segments (Test Type, Application, End-use, Brand), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
Latent Tuberculosis Infection Detection Market size was assessed at USD 1.92 Billion in 2025 and is poised to grow at a 5.5% CAGR between 2026 and 2035, surpassing USD 3.28 Billion by 2035. The industry revenue for 2026 is calculated at USD 2.01 billion.
Get more details on this report
Request Free Sample ReportLatent Tuberculosis Infection Detection Market Intelligence Snapshot
Regional Market Dynamics
- Asia Pacific held a 46.00% share in 2025, supported by large-scale screening programs, sustained testing demand, and broad diagnostic activity across laboratories, hospitals, and public health initiatives.
- North America is projected to grow at a 6.22% CAGR as targeted screening, preventive care integration, and wider adoption of advanced diagnostic methods increase testing demand among at-risk populations.
Segment Momentum
- The Tuberculin Skin Test leads with a 67.9% share in 2025 due to widespread clinical familiarity, established screening programs, and continued use in large-scale testing environments across routine care pathways.
- Household contacts are the fastest-growing segment as exposure-based screening gains importance, with early identification of infection risk driving stronger uptake of targeted latent tuberculosis detection and follow-up care.
Market Expansion Drivers
- Government TB eradication initiatives and increased funding expanding diagnostic screening programs globally.
- Rising prevalence of latent TB and HIV co-infection driving demand for early detection diagnostics.
- Expansion of advanced immunoassay and molecular diagnostic technologies improving detection accuracy and accessibility.
Leading Market Participants
Global Market Forecast Snapshot
Market Outlook
Leading companies in the latent tuberculosis infection detection market include QIAGEN N.V. (Netherlands), bioMérieux SA (France), Revvity, Inc. (United States), SD Biosensor, Inc. (South Korea), Sanofi S.A. (France), ARKRAY, Inc. (Japan), Serum Institute of India Pvt. Ltd. (India), Wantai BioPharm Co., Ltd. (China), Lionex GmbH (Germany), Par Pharmaceutical, Inc. (United States).Regional and Segment Outlook
Asia PacificMarket Growth Drivers and Industry Trends
National TB elimination strategies and donor-backed public health funding are widening the use of preventive screening in high-risk populations, which directly supports demand in the latent tuberculosis infection detection market. When governments embed latent TB testing into immigration health checks, workplace screening for healthcare staff, prison health programs, and contact tracing protocols, procurement shifts from episodic purchasing to planned volume-based acquisition of tuberculin skin tests, interferon-gamma release assays, and supporting laboratory services. This policy-led expansion also improves reimbursement pathways and programmatic adoption, making latent tuberculosis infection detection market growth closely tied to the scale and continuity of publicly financed screening campaigns.
Rising prevalence of latent TB and HIV co-infection increasing demand for early detection diagnostics
The growing overlap between latent TB and immunocompromised HIV-positive populations is increasing clinical reliance on early detection tools that can identify infection before progression to active disease. In practice, this pushes hospitals, infectious disease clinics, and public health programs to incorporate routine latent TB testing into HIV care pathways, since untreated latent infection carries greater management urgency in these patients. That integration is reinforcing market demand in the latent tuberculosis infection detection market for assays that fit targeted screening protocols, support treatment decisions, and reduce the risk of missed infections in populations already under continuous medical surveillance.
Expansion of advanced immunoassay and molecular diagnostic technologies improving detection accuracy and accessibility
Improving assay performance and wider access to modern laboratory platforms are reshaping test selection in the latent tuberculosis infection detection market by making screening more reliable and operationally feasible. Advanced immunoassays help clinicians move away from methods affected by return-visit requirements and interpretation variability, while molecular and automated diagnostic workflows strengthen confidence in large-scale screening programs run by hospitals, reference labs, and national TB control agencies. As these technologies become more available through broader instrument installation, centralized lab networks, and streamlined processing, they are increasing market penetration by lowering practical barriers to adoption and aligning latent tuberculosis infection detection market offerings with real-world screening needs.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Government TB eradication initiatives and increased funding expanding diagnostic screening programs globally | 2.00% | High | Asia Pacific, North America | High | Near Term |
| Rising prevalence of latent TB and HIV co-infection driving demand for early detection diagnostics | 1.80% | High | Asia Pacific, Africa | High | Mid Term |
| Expansion of advanced immunoassay and molecular diagnostic technologies improving detection accuracy and accessibility | 1.60% | Moderate | North America, Europe | Emerging | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
Asia Pacific held a 46.00% share of the latent tuberculosis infection detection market in 2025, supported by the region’s large testing base and sustained demand for screening across countries with a meaningful tuberculosis burden. Its leadership is aided by the practical need for broad population-level detection, including screening among high-risk groups and routine use of diagnostic programs in public health systems. This keeps testing volumes elevated and supports consistent market activity across laboratories, hospitals, and community-focused detection initiatives.
North America is projected to expand at a 6.22% CAGR over the forecast period in the latent tuberculosis infection detection market, driven by more targeted screening practices and wider use of advanced diagnostic methods in clinical settings. Growth is being accelerated by stronger emphasis on identifying latent infection in at-risk populations, where testing is increasingly integrated into preventive care, occupational health protocols, and immigration-related health assessments. In practice, this raises demand for accurate and scalable detection workflows across healthcare providers and diagnostic networks.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Precision Diagnostic AdoptionGermany emphasizes accurate latent tuberculosis infection detection through standardized testing protocols and laboratory quality assurance. Healthcare institutions are adopting modern diagnostic tools that improve clinical decision-making and screening efficiency.
France 🇫🇷
Risk-Based Detection StrategyFrance is reinforcing latent tuberculosis infection detection through focused screening of at-risk individuals and improved diagnostic pathways. Healthcare authorities encourage accurate testing to strengthen preventive care and reduce future disease burden.
Italy 🇮🇹
Expanded Clinical ScreeningItaly is enhancing latent tuberculosis infection detection by increasing screening within healthcare facilities and vulnerable populations. Diagnostic providers are supporting clinicians with dependable testing solutions that facilitate timely preventive treatment decisions.
Japan 🇯🇵
Preventive Testing FocusJapan supports latent tuberculosis infection detection through preventive screening initiatives targeting vulnerable patient groups. Healthcare providers are emphasizing reliable diagnostic methods that enable timely preventive treatment before disease progression.
South Korea 🇰🇷
Public Health SurveillanceSouth Korea continues strengthening latent tuberculosis infection detection through coordinated surveillance programs and expanded diagnostic capacity. Clinical laboratories are supporting broader screening efforts with efficient and standardized testing practices.
United States 🇺🇸
Targeted Screening ProgramsThe U.S. latent tuberculosis infection detection market prioritizes screening among high-risk populations using advanced diagnostic technologies. Healthcare providers continue refining testing strategies that enable earlier intervention and support public health objectives.
Segment Leadership and Growth Trends
Latent Tuberculosis Infection Detection Market Share (%), Test Type, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportWithin the latent tuberculosis infection detection market, Tuberculin Skin Test (TST) held the strongest position in 2025 with a 67.9% share. Its continued dominance is rooted in broad clinical familiarity, established use across routine screening programs, and practical suitability for large-scale testing environments where providers rely on methods already embedded in care pathways. In the latent tuberculosis infection detection market, TST maintains leadership because it remains a widely recognized first-line option in settings that prioritize accessibility and operational continuity.
Interferon Gamma Released Assay (IGRA) is emerging as the fastest-growing test type in the latent tuberculosis infection detection market as screening programs place greater emphasis on more targeted diagnostic approaches. Its momentum is supported by increasing preference for testing methods that fit evolving clinical requirements, especially where providers seek stronger confidence in identifying latent infection within more structured and risk-focused screening workflows. Compared with conventional skin testing, IGRA is gaining traction as healthcare systems refine testing strategies toward settings that can support more advanced laboratory-based assessment.
Application Segment Analysis: PLHIV (Largest Segment) vs Household Contacts with Pulmonary TB (Fastest-Growing Segment)
PLHIV accounted for the largest application in the latent tuberculosis infection detection market in 2025, capturing a 44.73% share. This leadership reflects the sustained need to screen populations with elevated vulnerability to tuberculosis progression, making latent infection detection a routine and necessary part of clinical management in this group. The latent tuberculosis infection detection market continues to see strong demand from PLHIV screening because testing is closely tied to ongoing monitoring and preventive care decisions in immunocompromised patients.
Household Contacts with Pulmonary TB represent the fastest-growing application in the latent tuberculosis infection detection market, encouraged by the practical need to identify transmission risk early among individuals with direct exposure. Growth in this segment is supported by the increasing focus on contact-based screening pathways, where testing is prioritized for people most likely to have recent exposure and therefore higher immediate relevance for follow-up care. Relative to broader application groups, this segment is gaining momentum because exposure-linked screening creates a clearer and more urgent use case for latent tuberculosis infection detection.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Test Type | Tuberculin Skin Test (TST), Interferon Gamma Released Assay (IGRA) | Tuberculin Skin Test (TST) | Interferon Gamma Released Assay (IGRA) |
| Application | Household Contacts with Pulmonary TB, PLHIV, Others | PLHIV | Household Contacts with Pulmonary TB |
| End-use | Diagnostic Laboratories, Hospitals/clinics, Academic & Research Institutions | Diagnostic Laboratories | Diagnostic Laboratories |
| Brand | QFT-Plus (QuantiFERON-TB Gold Plus), Others | QFT-Plus (QuantiFERON-TB Gold Plus) | QFT-Plus (QuantiFERON-TB Gold Plus) |
Competitive Landscape and Market Positioning
1. QIAGEN N.V. (Netherlands)
2. bioMérieux SA (France)
3. Revvity Inc. (United States)
4. SD Biosensor Inc. (South Korea)
5. Sanofi S.A. (France)
6. ARKRAY Inc. (Japan)
7. Serum Institute of India Pvt. Ltd. (India)
8. Wantai BioPharm Co. Ltd. (China)
9. Lionex GmbH (Germany)
10. Par Pharmaceutical Inc. (United States)
The latent tuberculosis infection detection market is evolving through improved diagnostic tools that enhance early identification and screening accuracy. Continuous innovation is strengthening test sensitivity and reliability. Expanding research collaborations are also accelerating development of next-generation diagnostic solutions.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Revvity | Feb-25 | Revvity received FDA approval for an improved automated latent TB infection testing workflow integrating the Auto-Pure liquid handling platform with the T-SPOT TB assay. The approval enhances laboratory automation and increases testing efficiency and throughput in clinical settings using IGRA-based TB diagnostics. |
| Revvity | Apr-25 | Revvity received FDA clearance for the Auto-Pure 2400 system integrated with the T-SPOT.TB assay, enabling higher-throughput IGRA testing in U.S. reference laboratories. The development strengthens the company’s automated TB screening capabilities and supports scaling of latent TB diagnostic workflows. |
| Revvity | Nov-23 | Revvity launched its T-SPOT TB test in India at MICROCON, expanding access to IGRA-based latent TB screening in a high-burden market. The company positioned the assay as the only FDA-approved ELISPOT-based IGRA test, reinforcing its competitive differentiation in TB diagnostics. |
| QIAGEN | Mar-24 | QIAGEN entered a global partnership with the International Panel Physicians Association to educate panel physicians on updated tuberculosis screening requirements, with emphasis on IGRA-based testing. The initiative supports broader adoption and standardization of latent TB screening practices among international healthcare providers. |
| QIAGEN | Feb-23 | QIAGEN achieved CE marking under the EU IVDR regulation for its QuantiFERON-TB Gold Plus test, replacing the previous IVDD framework. The certification strengthens regulatory compliance and supports continued commercialization of its leading IGRA-based tuberculosis blood test in the European market. |
| QIAGEN | Mar-25 | QIAGEN filed a patent infringement lawsuit against bioMérieux to protect its QuantiFERON technology in latent tuberculosis testing. The legal action reflects efforts to defend intellectual property and maintain competitive positioning in the IGRA-based TB diagnostics market. |
| bioMérieux | Apr-24 | bioMérieux obtained CE marking for its VIDAS KUBE automated immunoassay system, including support for VIDAS TB-IGRA testing. The approval expands the company’s automated tuberculosis screening capabilities and enhances its presence in latent TB diagnostic workflows across clinical laboratories. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
Latent Tuberculosis Infection Detection Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
Latent Tuberculosis Infection Detection Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchHow big is the latent tuberculosis infection detection market?
How is the latent tuberculosis infection detection industry projected to perform over the next decade?
How are government-led TB screening initiatives influencing demand in the latent tuberculosis infection detection market?
How is diagnostic technology advancement improving adoption of latent tuberculosis infection detection solutions?
Why does the Tuberculin Skin Test remain the dominant test type in latent tuberculosis detection?
What is driving increased screening among household contacts with pulmonary TB?
Why does Asia Pacific dominate the latent tuberculosis infection detection market?
What is driving North America's growth in the latent tuberculosis infection detection market?
Who are the major participants shaping the latent tuberculosis infection detection landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization